World Class Orthopedic Care at Home in Southwest Montana. (406) 586-8029
This is a non-randomized study, meaning that all patients who meet the eligibility criteria and volunteer to participate in the SAGE clinical study will receive GelrinC treatment.
In the clinical study, GelrinC will be used to fill a cartilage defect. It is intended to be resorbed by the body over time and be replaced by new tissue. GelrinC is composed of a synthetic material called PEG-DA and a structurally modified (denatured) protein called fibrinogen. These two materials have been used separately in medical products for other conditions, but in GelrinC are used together for cartilage repair.
GelrinC is approved for sale and marketing in the European community. It has been studied clinically in Europe in more than 50 patients and results suggested that GelrinC can provide substantial improvement in pain and function. The SAGE clinical study will further evaluate the potential benefits and the potential risks associated with GelrinC.
Because this is an FDA regulated clinical study, specific criteria must be followed to determine who is eligible for inclusion. A patient must meet all of these criteria to be included in the study. Final eligibility for the study will be determined by a study investigator (surgeon).
If you are between 18 and 50 years old, are suffering from pain in only one knee and can provide informed consent, then you may be eligible for this study.
For more information, please contact Dr. O'Brien or visit www.gelrinc.com.
CAUTION: Investigational Device. Limited by Federal (USA) Law to Investigational Use.